Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 9/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | GRM6 | O15303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29533592 | 1.00 | AR (0.40) | AREGLN2KDM4EUSP2ALDH1A1 | |
| SCHEMBL152108 | 0.83 | EGLN2 (0.43) | AREGLN2KDM4EUSP2ALDH1A1 | |
| SCHEMBL13216259 | 0.82 | AR (0.44) | AREGLN2TSHRTRPV4CYP11B1 | |
| SCHEMBL9340535 | 0.80 | EGLN2 (0.40) | AREGLN2KDM4EUSP2ALDH1A1 | |
| SCHEMBL1196089 | 0.80 | AR (0.43) | ARKDM4EUSP2ALDH1A1TSHR | |
| SCHEMBL12957943 | 0.78 | TSHR (0.43) | AREGLN2ALDH1A1TSHRTRPV4 | |
| SCHEMBL15365364 | 0.78 | KDM4E (0.38) | ARKDM4EUSP2ALDH1A1TSHR | |
| SCHEMBL6364089 | 0.78 | TRPV4 (0.42) | ARTSHRTRPV4CYP11B1CYP11B2 | |
| SCHEMBL9575173 | 0.77 | GRM6 (0.41) | ARKDM4EUSP2ALDH1A1TSHR | |
| SCHEMBL15594078 | 0.75 | AR (0.41) | ARTSHRTRPV4CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570631-B2 | Substituted N-(4-(pyrimidin and pyridin-4-yl)benzylcarboxamides and its use for treating disorders responsive to inhibition of Btk | BIOGEN MA INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4051680-B1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12391697-B2 | Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-12240838-B2 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-20240343681-A1 | MOLECULES HAVING PESTICIDAL UTILITY AND INTERMEDIATES AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2024-10-17 | — | — | US | disclosed |
| US-20240327380-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2024-10-03 | — | — | US | disclosed |
| EP-4313939-A1 | MOLECULES HAVING PESTICIDAL UTILITY AND INTERMEDIATES AND PROCESSES RELATED THERETO | Corteva Agriscience LLC (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117098750-A | Molecules having pesticidal utility, and intermediates and methods related thereto | 科迪华农业科技有限责任公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-116917279-A | BTK inhibitors | 渤健马萨诸塞州股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-3793994-B1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2021087112-A1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| WO-2021087112-A1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| EP-3793994-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| US-10899753-B2 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2021-01-26 | — | — | US | disclosed |
| WO-2020232330-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2020-11-19 | — | — | WO | disclosed |
| WO-2020232330-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2020-11-19 | — | — | WO | disclosed |
| EP-2504010-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | Merck Sharp & Dohme Corp. (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011062885-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2011-05-26 | — | — | WO | disclosed |
| US-7405234-B2 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| CN-1894235-A | N-(4-carbamimidoyl-benzyl) -2-alkoxy-2-heterocyclyl acetamides as inhibitors of the formation of coagulation factors xa, ixa and thrombin induced by factor viia | HOFFMANN LA ROCHE (CH) | 2007-01-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240838-B2 | Inhibiting agents for Bruton's tyrosine kinase | ABL1, BTK, LYN | AR 4570/4885EGLN2 1628/4885KDM4E 1230/4885 |
| US-12570631-B2 | Substituted N-(4-(pyrimidin and pyridin-4-yl)benzylcarboxamides and its use for treating disorders responsive to inhibition of Btk | BTK, LYN, SYK | AR 3088/4885EGLN2 4308/4885KDM4E 1853/4885 |
| US-20240343681-A1 | MOLECULES HAVING PESTICIDAL UTILITY AND INTERMEDIATES AND PROCESSES RELATED THERETO | ACHE, DDT, MLYCD | AR 4360/4885EGLN2 3986/4885KDM4E 1669/4885 |
| US-20240327380-A1 | BTK INHIBITORS | BTK, SYK, LYN | AR 2256/4885EGLN2 4545/4885KDM4E 1077/4885 |
| US-10899753-B2 | Inhibiting agents for Bruton's tyrosine kinase | ABL1, BTK, LYN | AR 4570/4885EGLN2 1628/4885KDM4E 1230/4885 |
| US-12391697-B2 | Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase | ABL1, CDK1, CDK2 | AR 3751/4885EGLN2 1778/4885KDM4E 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.